Scottish blood service secures prion-filter patent:
This article was originally published in Clinica
The European Patent Office has granted the Scottish National Blood Transfusion Service (SNBTS) a patent for its technique for removing abnormal prion protein from solution containing biological products. The "depth filtration" technique involved has "no unacceptable effects on the nature or biological activity of the product", says the SNBTS, which developed the method to support the manufacture of plasma products, such as albumin and immune globulin. "Although we have not used UK plasma for fractionation since 1998, this technology is a welcome additional safety measure that can be applied worldwide," says the SNBTS. It believes that the technology has a "wide range of applications, not only in plasma products, but also in other bio-processing technologies that require risk reduction, such as cell culture media". The announcement coincides with the publication of the UK's 2003 Serious Hazards of Transfusion report (see Clinica No 1117), which features the first suspected case of transfusion-transmitted vCJD, identified following the death of a transfusion recipient.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.